Developer docs
API playgroundTry for free, no card

Search company profiles

Imbio

Full company profile

uuid00043dw

Namestring
Imbio
Websiteurl
imbio.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Imbio is a Minneapolis-based medical imaging software company founded in 2005 that develops AI-powered diagnostic tools for healthcare providers. The company's software applies artificial intelligence to medical imaging across five clinical specialties: radiology, cardiology, oncology, pathology, and neurology. Imbio is positioned in third-party market research as a key player in the AI diagnostics market, which is projected to grow from $2,680.3 million in 2026 to $10,416.2 million by 2033, and operates within the broader AI in MRI market projected to reach $9.54 billion by 2030.

The company's technology stack centers on AI algorithms applied to diagnostic imaging workflows, though specific model architectures, training data assets, and integration details are not publicly disclosed. Imbio competes alongside significantly larger and more capital-intensive vendors including GE Healthcare, Canon Medical Systems USA, Aidoc, Vuno, Alivecor, and Digital Diagnostics, but operates as a focused niche player with 11-50 employees and approximately $4.08 million in cumulative disclosed funding across three rounds (2013, 2015, and 2017, the last led by Invenshure).

Imbio's business model is not publicly disclosed, and no specific pricing structure, revenue figures, customer logos, distribution channels, or certifications/compliance details are available. The company is led by CEO David Hannes and Chairman Danny J. Cunagin. Imbio remains a private, for-profit entity headquartered in Minneapolis, Minnesota, and serves healthcare providers as its primary customer segment across multiple diagnostic use cases.

Short descriptiontext

Imbio is a Minneapolis-based medical imaging AI software company founded in 2005, developing diagnostic tools applied across radiology, cardiology, oncology, pathology, and neurology for healthcare providers. The company operates as a focused niche player in the broader AI diagnostics market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical imaging software, AI diagnostics, radiology AI, imaging analysis, diagnostic algorithms
Industry4 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Medical Imaging AI Software
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Imbio develops medical imaging software solutions that use artificial intelligence to deliver diagnostic capabilities across multiple clinical specialties. The company's offerings are designed to improve diagnostic accuracy and efficiency in medical imaging interpretation, serving healthcare providers in radiology, cardiology, oncology, pathology, and neurology.

Differentiator
Functional benefit
Problem solved
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GE Healthcare is a global medical imaging equipment and software incumbent that increasingly embeds AI capabilities into its imaging platforms and Edison platform. It is comparable to Imbio as a large incumbent competing in AI diagnostics, though it offers imaging AI as part of a broader imaging equipment portfolio.

TypeDirect peer
Description

AliveCor builds AI-enabled cardiac diagnostics through ECG-based hardware and software. It is comparable to Imbio as a key player in the AI diagnostics market competing across cardiology use cases alongside Imbio's cardiology imaging AI capabilities.

TypeBroad incumbent
Description

Canon Medical Systems is a global imaging equipment vendor (CT, MRI, ultrasound) integrating AI into its modality platforms. It is comparable to Imbio as a broad incumbent competing in AI-enabled imaging diagnostics, with AI embedded into the imaging equipment stack rather than offered standalone.

TypeDirect peer
Description

Viz.ai is a healthcare AI company specializing in AI-powered care coordination and image analysis, particularly for stroke and other time-sensitive conditions. It is comparable to Imbio as a medical imaging AI vendor serving hospitals with FDA-cleared clinical decision-support software.

TypeRegional player
Description

VUNO is a South Korea-based medical AI company developing diagnostic AI solutions across radiology, cardiology, and pathology. It is comparable to Imbio as a key player in the AI diagnostics market per industry analyst listings, though its primary geographic focus is Asia rather than the U.S.

TypeDirect peer
Description

Aidoc is a venture-backed clinical AI platform that deploys AI algorithms across CT imaging to triage and detect acute conditions. It is directly comparable to Imbio as a standalone radiology AI software vendor selling workflow-integrated decision-support tools to hospitals and imaging centers.

TypeDirect peer
Description

Digital Diagnostics is an AI diagnostics company developing autonomous diagnostic systems, including in ophthalmology and dermatology. It is comparable to Imbio as an AI-driven clinical diagnostics software company competing in the same AI diagnostics market segment.

TypeDirect peer
Description

HeartFlow offers AI-enabled non-invasive cardiac diagnostics from CT imaging to assess coronary artery disease. It is comparable to Imbio as a specialty-focused AI imaging software company delivering clinical decision support to hospitals in cardiology and adjacent cardiovascular imaging.

TypeDirect peer
Description

Arterys provides cloud-based AI medical imaging analytics, including cardiac and oncology applications delivered through a SaaS platform. It is comparable to Imbio as a vendor of cloud-delivered AI imaging software serving radiology and cardiology specialists.

10Zebra Medical Vision (Nanox AI)
TypeDirect peer
Description

Zebra Medical Vision, now operating as Nanox AI, develops AI algorithms for medical imaging interpretation across multiple modalities and pathologies. It competes directly with Imbio in multi-specialty radiology AI imaging analytics for healthcare providers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Imbio

Medical Imaging AI Softwareimbio.com

Imbio is a Minneapolis-based medical imaging AI software company founded in 2005, developing diagnostic tools applied across radiology, cardiology, oncology, pathology, and neurology for healthcare providers. The company operates as a focused niche player in the broader AI diagnostics market.

What Imbio does

Imbio is a Minneapolis-based medical imaging software company founded in 2005 that develops AI-powered diagnostic tools for healthcare providers. The company's software applies artificial intelligence to medical imaging across five clinical specialties: radiology, cardiology, oncology, pathology, and neurology. Imbio is positioned in third-party market research as a key player in the AI diagnostics market, which is projected to grow from $2,680.3 million in 2026 to $10,416.2 million by 2033, and operates within the broader AI in MRI market projected to reach $9.54 billion by 2030.

The company's technology stack centers on AI algorithms applied to diagnostic imaging workflows, though specific model architectures, training data assets, and integration details are not publicly disclosed. Imbio competes alongside significantly larger and more capital-intensive vendors including GE Healthcare, Canon Medical Systems USA, Aidoc, Vuno, Alivecor, and Digital Diagnostics, but operates as a focused niche player with 11-50 employees and approximately $4.08 million in cumulative disclosed funding across three rounds (2013, 2015, and 2017, the last led by Invenshure).

Imbio's business model is not publicly disclosed, and no specific pricing structure, revenue figures, customer logos, distribution channels, or certifications/compliance details are available. The company is led by CEO David Hannes and Chairman Danny J. Cunagin. Imbio remains a private, for-profit entity headquartered in Minneapolis, Minnesota, and serves healthcare providers as its primary customer segment across multiple diagnostic use cases.

Imbio firmographics

Firmographics
Name
Imbio
Website
https://imbio.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Imbio is a Minneapolis-based medical imaging AI software company founded in 2005, developing diagnostic tools applied across radiology, cardiology, oncology, pathology, and neurology for healthcare providers. The company operates as a focused niche player in the broader AI diagnostics market.
Ownership category
akta.pro rank

Imbio industry classification

Industry
Product category
Medical Imaging AI Software
NAICS
Software Publishers (513210)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Medical imaging software
  • AI diagnostics
  • Radiology AI
  • Imaging analysis
  • Diagnostic algorithms

Where Imbio is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Markets served

Imbio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Imbio product offering

Product offering

Core offering

Imbio develops medical imaging software solutions that use artificial intelligence to deliver diagnostic capabilities across multiple clinical specialties. The company's offerings are designed to improve diagnostic accuracy and efficiency in medical imaging interpretation, serving healthcare providers in radiology, cardiology, oncology, pathology, and neurology.

Differentiator

Problem solved

Functional benefit

Companies that use Imbio

Customer profile

Segments1 record

Ideal customer profiles1 record

Imbio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Imbio partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Imbio competitors and assessment

Company assessment

Broad incumbents

  • GE Healthcare: GE Healthcare is a global medical imaging equipment and software incumbent that increasingly embeds AI capabilities into its imaging platforms and Edison platform. It is comparable to Imbio as a large incumbent competing in AI diagnostics, though it offers imaging AI as part of a broader imaging equipment portfolio.
  • Canon Medical Systems USA: Canon Medical Systems is a global imaging equipment vendor (CT, MRI, ultrasound) integrating AI into its modality platforms. It is comparable to Imbio as a broad incumbent competing in AI-enabled imaging diagnostics, with AI embedded into the imaging equipment stack rather than offered standalone.

Direct peers

  • AliveCor: AliveCor builds AI-enabled cardiac diagnostics through ECG-based hardware and software. It is comparable to Imbio as a key player in the AI diagnostics market competing across cardiology use cases alongside Imbio's cardiology imaging AI capabilities.
  • Viz.ai: Viz.ai is a healthcare AI company specializing in AI-powered care coordination and image analysis, particularly for stroke and other time-sensitive conditions. It is comparable to Imbio as a medical imaging AI vendor serving hospitals with FDA-cleared clinical decision-support software.
  • Aidoc: Aidoc is a venture-backed clinical AI platform that deploys AI algorithms across CT imaging to triage and detect acute conditions. It is directly comparable to Imbio as a standalone radiology AI software vendor selling workflow-integrated decision-support tools to hospitals and imaging centers.
  • Digital Diagnostics: Digital Diagnostics is an AI diagnostics company developing autonomous diagnostic systems, including in ophthalmology and dermatology. It is comparable to Imbio as an AI-driven clinical diagnostics software company competing in the same AI diagnostics market segment.
  • HeartFlow: HeartFlow offers AI-enabled non-invasive cardiac diagnostics from CT imaging to assess coronary artery disease. It is comparable to Imbio as a specialty-focused AI imaging software company delivering clinical decision support to hospitals in cardiology and adjacent cardiovascular imaging.
  • Arterys: Arterys provides cloud-based AI medical imaging analytics, including cardiac and oncology applications delivered through a SaaS platform. It is comparable to Imbio as a vendor of cloud-delivered AI imaging software serving radiology and cardiology specialists.
  • Zebra Medical Vision (Nanox AI): Zebra Medical Vision, now operating as Nanox AI, develops AI algorithms for medical imaging interpretation across multiple modalities and pathologies. It competes directly with Imbio in multi-specialty radiology AI imaging analytics for healthcare providers.

Regional players

  • VUNO: VUNO is a South Korea-based medical AI company developing diagnostic AI solutions across radiology, cardiology, and pathology. It is comparable to Imbio as a key player in the AI diagnostics market per industry analyst listings, though its primary geographic focus is Asia rather than the U.S.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights4 records

Customer concentration

Imbio social profiles

Digital presence

Imbio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Imbio leadership team

Management profile

Number of profiles

Profiles2 records

Imbio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Imbio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imbio

What does Imbio do?

Imbio develops medical imaging software solutions that use artificial intelligence to deliver diagnostic capabilities across multiple clinical specialties. The company's offerings are designed to improve diagnostic accuracy and efficiency in medical imaging interpretation, serving healthcare providers in radiology, cardiology, oncology, pathology, and neurology.

When was Imbio founded?

Imbio was founded in 2012. It employs 1 to 10 people.

Where is Imbio based?

Imbio is headquartered in Minneapolis, United States, in the North America region.

Who are Imbio's main competitors?

Broad incumbents on record are GE Healthcare and Canon Medical Systems USA. Direct peers are AliveCor, Viz.ai, Aidoc, Digital Diagnostics, HeartFlow, Arterys and Zebra Medical Vision (Nanox AI). VUNO is listed as a regional player.

Does Imbio have an API?

No public API is recorded for Imbio.

What industry is Imbio in?

Imbio's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comArtificial Intelligence Diagnostics Market Set to Witness Significant Growth by 2025-2032 | Vuno Inc., CHC Healthcare Group, Aidoc, Imbio, Alivecor Inc.The AI diagnostics market is projected to grow from USD 2,207.8 million in 2025 to USD 8,481.6 million by 2032, a CAGR of 21.2%. The study by Coherent Market Insights covers key players like Vuno, Aidoc, and GE Healthcare, with segmentation by component and diagnostics type.PR Newswire4DMedical and Imbio Merge to Create Comprehensive Cardiothoracic Image Analysis Portfolio4DMedical announced a binding agreement to acquire Imbio, a portfolio company of Invenshure, to combine their lung imaging technologies. The acquisition aims to create a comprehensive cardiothoracic image analysis portfolio, expanding 4DMedical's addressable market and enabling US commercialization through Imbio's contracts.ImbioImbio to be Acquired by 4DMedical Creating Comprehensive Cardiothoracic Image Analysis Portfolio4DMedical has entered a binding agreement to acquire Imbio, combining their respective technologies to create a comprehensive cardiothoracic image analysis portfolio. The merger integrates Imbio’s anatomical and tissue analysis with 4DMedical’s functional imaging capabilities to provide broader diagnostic insights for lung and heart diseases.PR NewswireImbio Partners with MEDICAL-NOTE to Expand Image Analysis Tool Offering to Clinicians across ItalyImbio and MEDICAL-NOTE announced a partnership to expand access to Imbio's AI-based image analysis technologies for lung diseases across Italy. The collaboration integrates Imbio's Lung Density and Texture Analysis tools into MEDICAL-NOTE's LUNG-NOTE application, enabling clinicians to utilize quantitative imaging data for improved diagnostic and treatment decisions.PR NewswireOlympus Makes SeleCT™ QCT Analysis Available Nationwide via the Nuance AI Marketplace to Increase Access to Spiration Valve System TherapyOlympus Corporation announced the launch of SeleCT Connect™, making its SeleCT™ Quantitative Computer Tomography analysis service available to more than 9,000 healthcare facilities in the U.S. through the Nuance AI Marketplace. The service streamlines patient screening for the Spiration Valve System, an FDA-designated breakthrough device for treating COPD patients, by automating the process of sending CT studies for AI-powered analysis and returning results directly to patient records. The program is a collaboration between Imbio, which provides the AI-based QCT analysis, and Nuance Communications, which contributes its cloud-based diagnostic imaging network.PR NewswireImbio and Riverain Technologies Partner to Offer a Comprehensive AI-Powered Lung Health SolutionImbio, a medical imaging AI provider for chronic lung diseases, and Riverain Technologies, a clinical AI company focused on lung nodule detection, have announced a partnership to deliver a comprehensive AI-powered lung health solution for clinicians and health systems. The combined offering integrates Imbio's quantitative analysis tools for COPD, emphysema, and interstitial lung diseases with Riverain's ClearRead solutions for early lung nodule detection, creating a more complete lung health platform. The partnership is designed to support lung cancer screening programs and provide clinicians with more personalized diagnostic information for patient care decisions.PR NewswireFlywheel and Imbio Partner to Deliver a Comprehensive Solution for Lung Disease DiscoveryFlywheel Exchange, Inc. and Imbio have announced a partnership to accelerate lung disease discovery, diagnosis, and treatment in the Life Sciences sector by integrating Imbio's FDA-cleared imaging biomarkers onto Flywheel's cloud-scale data management platform. The combined solution enables pharmaceutical companies and researchers to process large volumes of curated data using AI algorithms for disease diagnosis and progression analysis, improving cohort enrichment and clinical trial outcomes. The CEOs of both companies characterized the partnership as a natural fit that will enhance lung imaging research capabilities.PR NewswireImbio Partners with Heart&Lung Health Ltd to Serve the UK Market with Enhanced Quantitative Imaging ServicesImbio, a provider of AI solutions for medical imaging analysis, and Heart&Lung Health, a UK-based cardiothoracic consultancy firm, announced a partnership to integrate Imbio's quantitative imaging AI algorithms into Heart&Lung Health's subspecialty radiology workflows across the United Kingdom. The technology will enable automated analysis of CT thorax scans to identify lung and cardiac conditions without additional steps by radiologists, with results available upon receipt of scans. The partnership aims to support early diagnosis and treatment planning for patients with chronic lung diseases through improved workflow efficiency and data-driven insights for cardiothoracic radiologists.PR NewswireImbio Receives FDA 510(k) Clearance for New Cardiothoracic Imaging AlgorithmImbio received FDA 510(k) clearance for its RV/LV Analysis algorithm, an AI tool designed to automatically assess right ventricular dilation from medical imaging. This automated analysis provides clinicians with a key risk indicator for pulmonary conditions like pulmonary embolism directly within patient imaging studies.PR NewswireSpesana Partners with Imbio to Add Quantitative Imaging to Its Molecular Diagnostics Decision Support PlatformSpesana and Imbio have partnered to integrate quantitative imaging into Spesana's molecular diagnostics decision support platform, enhancing patient care. The partnership aims to improve diagnosis and treatment of chronic lung diseases, potentially reducing healthcare costs associated with conditions like COPD and emphysema. This collaboration intends to provide early detection and effective patient management solutions for these diseases.